Polyclonal Antibody to Protein Kinase B Alpha (PKBa)
| Code | Size | Price |
|---|
| PAC231Hu01-20ul | 20ul | £87.00 |
Quantity:
| PAC231Hu01-100ul | 100ul | £162.00 |
Quantity:
| PAC231Hu01-200ul | 200ul | £218.00 |
Quantity:
| PAC231Hu01-1ml | 1ml | £499.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
AKT1; AKT; PKB-A; Proto-oncogene c-Akt; RAC-Alpha Serine/Threonine-Protein Kinase; V-akt Murine Thymoma Viral Oncogene Homolog 1
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Protein Kinase B Alpha
Reactivity:
Mu;Ra;Ca;Po;Bo;Ga;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.01-3ug/mL;<br/>Immunohistochemistry: 5-30ug/mL;<br/>Immunocytochemistry: 5-30ug/mL;<br/>Optimal working dilutions must be determined by end user.
References
https://jgeb.springeropen.com/articles/10.1186/s43141-021-00118-1;
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Protein Kinase B Alpha (PKBa) | RPC231Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||